| A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer | Erlotinib | Phase 2 | Not yet recruiting | Korea University Anam Hospital | Nov 17, 2026 |
| A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Cetuximab | Phase 1 / Phase 2 | Not yet recruiting | Bristol-Myers Squibb | Nov 16, 2026 |
| A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation | Cetuximab | Phase 1 | Not yet recruiting | Boehringer Ingelheim | Nov 9, 2026 |
| A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer | Nimotuzumab | Phase 2 | Enrolling by invitation | Fudan University | Nov 6, 2026 |
| A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures | Panitumumab | Phase 1 | Not yet recruiting | University of Alabama at Birmingham | Nov 5, 2026 |
| Real-World Study: Panitumumab N01 vs Cetuximab Plus FOLFOX in First-Line RAS Wild-Type mCRC | Cetuximab, Panitumumab | — | Not yet recruiting | Fujian Medical University Union Hospital | Nov 4, 2026 |
| Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer Liver Metastases After Resection | Cetuximab | Phase 2 | Recruiting | Fudan University | Nov 4, 2026 |
| A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer | Cetuximab | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | Nov 4, 2026 |
| GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer | Cetuximab | Phase 3 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | Nov 3, 2026 |
| A KRAS Inhibitor in Participants With Advanced Solid Tumors | Cetuximab | Phase 1 / Phase 2 | Recruiting | Ensem Therapeutics | Nov 3, 2026 |
| Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases | Osimertinib | Phase 2 | Recruiting | Cho Ray Hospital | Nov 2, 2026 |
| A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation | Cetuximab | Phase 1 | Not yet recruiting | Hoffmann-La Roche | Oct 30, 2026 |
| Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Study | Nimotuzumab | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Oct 30, 2026 |
| A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2 | Icotinib | Phase 4 | Not yet recruiting | Zhou Chengzhi | Oct 28, 2026 |
| ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC | Osimertinib | Phase 3 | Not yet recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Oct 27, 2026 |
| Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer | Osimertinib | Early phase 1 | Recruiting | Oliver Jonas | Oct 23, 2026 |
| Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer | Pyrotinib | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Oct 23, 2026 |
| Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study | Firmonertinib | Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | Oct 16, 2026 |
| Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC | Osimertinib | Phase 2 | Recruiting | NYU Langone Health | Oct 15, 2026 |
| MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC | Aumolertinib | Not applicable | Not yet recruiting | Peking University People's Hospital | Oct 14, 2026 |
| An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer. | Aumolertinib | Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Oct 7, 2026 |
| A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma | Panitumumab | Phase 1 | Not yet recruiting | Genentech, Inc. | Oct 5, 2026 |
| Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC | Erlotinib, Gefitinib, Osimertinib, Aumolertinib, Icotinib | — | Recruiting | Tongji Hospital | Sep 23, 2026 |
| A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd | Pyrotinib | Phase 2 | Not yet recruiting | Fujian Medical University | Sep 23, 2026 |
| Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer | Gefitinib | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | Sep 21, 2026 |
| Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal Cancer | Panitumumab | Phase 1 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | Sep 21, 2026 |
| Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | Matuzumab, Nimotuzumab | Phase 2 | Not yet recruiting | Ke Hu | Sep 15, 2026 |
| Becotatug Vedotin Plus Pucotenlimab and Platinum Chemotherapy in Locally Advanced Epidermal Growth Factor Receptor (EGFR)-Positive Head and Neck Squamous Cell Carcinoma | Matuzumab | Phase 2 | Recruiting | Xuekui Liu | Sep 10, 2026 |
| Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab | Pyrotinib | — | Active, not recruiting | Beijing 302 Hospital | Sep 9, 2026 |
| Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma | Amivantamab | Phase 2 | Not yet recruiting | Latin American Cooperative Oncology Group | Sep 8, 2026 |
| Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC | Firmonertinib | Phase 2 | Not yet recruiting | Hubei Cancer Hospital | Sep 8, 2026 |
| Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer | Icotinib | — | Recruiting | Betta Pharmaceuticals Co., Ltd. | Sep 8, 2026 |
| Molecularly Tailored Therapy in Advanced Pancreatic Cancer | Erlotinib | Phase 2 | Not yet recruiting | Herlev Hospital | Sep 3, 2026 |
| JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure | Amivantamab | Phase 1 | Not yet recruiting | Yonsei University | Sep 2, 2026 |
| Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC | Pyrotinib | Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | Sep 1, 2026 |
| SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer | Pyrotinib | Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | Aug 26, 2026 |
| A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy | Lazertinib | Phase 2 | Recruiting | Samsung Medical Center | Aug 19, 2026 |
| A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer | Brigatinib | Phase 2 | Not yet recruiting | First Affiliated Hospital of Fujian Medical University | Aug 18, 2026 |
| Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma | Matuzumab | Phase 2 | Not yet recruiting | Sun Yat-sen University | Aug 17, 2026 |
| Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer | Pyrotinib | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | Aug 14, 2026 |
| Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma | Amivantamab | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | Aug 4, 2026 |
| Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma | Panitumumab | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | Aug 3, 2026 |
| Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer | Osimertinib | Phase 3 | Recruiting | National Taiwan University Hospital | Jul 31, 2026 |
| A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer | Nimotuzumab | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang University | Jul 30, 2026 |
| Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer | Neratinib | Phase 2 | Not yet recruiting | University of California, San Diego | Jul 27, 2026 |
| A Phase 2 Study of ABSK043 Combined With Osimertinib | Osimertinib | Phase 2 | Not yet recruiting | Abbisko Therapeutics Co, Ltd | Jul 17, 2026 |
| Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma | Nimotuzumab | Phase 3 | Recruiting | Sun Yat-sen University | Jul 16, 2026 |
| Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma | Nimotuzumab | Phase 2 | Not yet recruiting | Tianjin First Central Hospital | Jul 16, 2026 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure | Pyrotinib | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | Jul 16, 2026 |
| A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer | Lazertinib, Osimertinib, Aumolertinib | Phase 1 / Phase 2 | Recruiting | Voronoi, Inc | Jul 13, 2026 |
| First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations | Aumolertinib | Phase 2 | Not yet recruiting | Yongsheng Wang | Jul 13, 2026 |
| EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer | Cetuximab sarotalocan | Phase 1 / Phase 2 | Not yet recruiting | Brown University | Jul 13, 2026 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | Panitumumab | Phase 2 | Recruiting | Verastem, Inc. | Jun 22, 2026 |
| A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer | Firmonertinib | Phase 2 | Not yet recruiting | Anhui Provincial Cancer Hospital | Jun 22, 2026 |
| OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy | Brigatinib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | Jun 18, 2026 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer | Afatinib, Pyrotinib | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | Jun 17, 2026 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Panitumumab | Phase 2 | Recruiting | Verastem, Inc. | Jun 12, 2026 |
| PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC | Aumolertinib | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | Jun 12, 2026 |
| EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC | Aumolertinib | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | Jun 9, 2026 |
| Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma | Aumolertinib | Phase 2 | Recruiting | Taipei Medical University Hospital | Jun 3, 2026 |
| Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma | Firmonertinib | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | Jun 3, 2026 |
| Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | Nimotuzumab | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | May 22, 2026 |
| A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC | Amivantamab, Lazertinib | Phase 2 | Recruiting | Janssen Research & Development, LLC | May 14, 2026 |
| Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer | Amivantamab | — | Recruiting | GFPC Investigation | May 1, 2026 |
| Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment | Panitumumab | — | Not yet recruiting | Chirec | Apr 22, 2026 |
| Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma | Nimotuzumab | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Apr 17, 2026 |
| Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study) | Amivantamab, Lazertinib | Phase 2 | Not yet recruiting | Yonsei University | Apr 2, 2026 |
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma | Gefitinib | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | Mar 17, 2026 |
| A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens | Amivantamab, Lazertinib | Phase 4 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | Mar 13, 2026 |
| Therapy for Advanced NSCLC With EGFR 19delins Mutation | Gefitinib, Icotinib | Early phase 1 | Not yet recruiting | Fuzhou General Hospital | Mar 9, 2026 |
| Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations. | Amivantamab | Phase 2 | Recruiting | Fondazione Ricerca Traslazionale | Feb 6, 2026 |
| Zorifertinib With Osimertinib for NSCLC With Meningeal Progression | AZD-3759 | Phase 1 | Recruiting | Alpha Biopharma (Jiangsu) Co., Ltd. | Jan 23, 2026 |
| A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients | Erlotinib, Gefitinib | — | Not yet recruiting | Guangzhou University of Traditional Chinese Medicine | Jan 13, 2026 |
| Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer | Neratinib | Phase 2 | Not yet recruiting | Xijing Hospital | Jan 12, 2026 |
| Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma | Firmonertinib | Phase 2 | Recruiting | Hunan Cancer Hospital | Jan 2, 2026 |
| Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg | Firmonertinib | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | Dec 23, 2025 |
| A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting | Lazertinib | — | Recruiting | Janssen Research & Development, LLC | Nov 17, 2025 |
| Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer | CLN-081 | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | Nov 17, 2025 |
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations | Afatinib, Firmonertinib | Phase 3 | Recruiting | ArriVent BioPharma, Inc. | Sep 22, 2025 |
| High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC | Firmonertinib | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | Sep 19, 2025 |
| An External Control Arm Study in Non-Small Cell Lung Cancer | Lazertinib | — | Recruiting | N-Power Medicine | Sep 15, 2025 |
| RT for Adenocarcinoma/Adenosquamous Carcinoma | Neratinib | Phase 1 / Phase 2 | Active, not recruiting | Peking Union Medical College Hospital | Sep 4, 2025 |
| T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis | Neratinib, Lapatinib | Phase 2 | Recruiting | Fudan University | Sep 3, 2025 |
| A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases | Erlotinib, Gefitinib | — | Recruiting | Alpha Biopharma (Jiangsu) Co., Ltd. | Aug 27, 2025 |
| A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection | CLN-081 | Phase 3 | Recruiting | Taiho Oncology, Inc. | Aug 17, 2025 |
| Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study | Neratinib | — | Not yet recruiting | Hebei Medical University Fourth Hospital | Jun 13, 2025 |
| A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma | Afatinib | Phase 1 / Phase 2 | Active, not recruiting | West China Hospital | Jun 8, 2025 |
| Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population | Erlotinib | Phase 2 | Recruiting | Mayo Clinic | May 30, 2025 |
| Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations | Icotinib | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | May 2, 2025 |
| Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients | Neratinib | Not applicable | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Mar 24, 2025 |
| A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Matuzumab | Phase 2 | Recruiting | Shanghai Henlius Biotech | Mar 4, 2025 |
| Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy | Neratinib, Lapatinib | Early phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | Feb 14, 2025 |
| Using Tumor Models to Determine Treatments | Brigatinib, Neratinib | Phase 2 | Recruiting | University Health Network, Toronto | Feb 6, 2025 |
| FHND9041 Versus Afatinib for Non-small Cell Lung Cancer | Afatinib | Phase 3 | Enrolling by invitation | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Jan 6, 2025 |
| A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma | Afatinib | Phase 1 / Phase 2 | Recruiting | West China Hospital | Dec 31, 2024 |
| A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations | Matuzumab | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | Dec 16, 2024 |
| Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC | Afatinib | Phase 2 | Recruiting | Shandong Public Health Clinical Center | Nov 29, 2024 |
| A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases | Cetuximab sarotalocan | Phase 3 | Recruiting | Rakuten Medical, Inc. | Nov 21, 2024 |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Lazertinib | Phase 2 | Recruiting | Janssen Research & Development, LLC | Oct 31, 2024 |
| Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Afatinib | Phase 1 / Phase 2 | Recruiting | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Oct 18, 2024 |
| Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib | Brigatinib | Phase 2 | Recruiting | Groupe Francais De Pneumo-Cancerologie | Oct 1, 2024 |
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies | Erlotinib | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | Aug 9, 2024 |
| Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations | Icotinib | Phase 2 | Recruiting | Sun Yat-sen University | Jul 24, 2024 |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel | Erlotinib | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | Jul 3, 2024 |
| EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study | Afatinib | Phase 3 | Recruiting | Region Skane | Jul 3, 2024 |
| A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer | Lapatinib | Phase 3 | Recruiting | Tianjin Hemay Pharmaceutical Co., Ltd | Mar 15, 2024 |
| Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients | Gefitinib | Phase 1 / Phase 2 | Recruiting | China Medical University Hospital | Oct 6, 2023 |
| Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations | Icotinib | Phase 3 | Recruiting | Betta Pharmaceuticals Co., Ltd. | Sep 18, 2023 |
| REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | CLN-081 | Phase 3 | Active, not recruiting | Taiho Oncology, Inc. | Aug 3, 2023 |
| A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. | CLN-081 | Phase 2 | Recruiting | Taiho Oncology, Inc. | Aug 1, 2023 |
| A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY | Brigatinib | — | Active, not recruiting | Takeda | Feb 21, 2023 |
| A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) | Brigatinib | — | Active, not recruiting | Takeda | Feb 10, 2023 |
| Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC | Icotinib | Phase 2 | Recruiting | Guangdong Association of Clinical Trials | Sep 13, 2022 |
| Antineoplastic Drugs in Elderly Patients | Lapatinib | — | Recruiting | Shandong University | Jul 20, 2022 |
| Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations | Gefitinib | Phase 3 | Recruiting | Instituto Nacional de Cancerologia de Mexico | Jul 6, 2022 |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Brigatinib | Phase 1 / Phase 2 | Recruiting | Nuvalent Inc. | May 20, 2022 |
| Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) | Brigatinib | Phase 2 | Active, not recruiting | Intergroupe Francophone de Cancerologie Thoracique | Jan 20, 2022 |
| Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | Necitumumab | Phase 1 / Phase 2 | Active, not recruiting | Jonsson Comprehensive Cancer Center | Feb 26, 2020 |
| Implantable Microdevice In Primary Brain Tumors | Lapatinib | Early phase 1 | Recruiting | Oliver Jonas | Oct 23, 2019 |
| A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer | CLN-081 | Phase 1 / Phase 2 | Active, not recruiting | Cullinan Therapeutics Inc. | Jul 30, 2019 |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | Necitumumab | Phase 2 | Active, not recruiting | AstraZeneca | May 10, 2019 |
| A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer | Mobocertinib | Phase 1 | Active, not recruiting | Takeda | Jan 17, 2019 |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | Nazartinib | Phase 1 | Active, not recruiting | Novartis Pharmaceuticals | Nov 6, 2017 |
| Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | Nazartinib | Phase 2 | Active, not recruiting | Novartis Pharmaceuticals | Feb 2, 2017 |
| Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor | Necitumumab | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | Jul 14, 2015 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | Sapitinib | Phase 2 | Active, not recruiting | UNICANCER | Nov 24, 2014 |
| Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment | Lapatinib | Phase 2 | Recruiting | Centre Leon Berard | Jan 7, 2014 |
| Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | Lapatinib | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | Sep 20, 2013 |
| Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | Lapatinib | Phase 2 | Active, not recruiting | City of Hope Medical Center | Jan 10, 2011 |